Boardroom Alpha
Boardroom Alpha
CTS · Current Report (Form 8-K) · Filed May 19, 2026

Cts Corp — Current Report (Form 8-K)

Form
8-K
Filed
May 19, 2026
Period
May 14, 2026
Ticker
CTS
Accession
0001193125-26-230702
Boardroom Alpha · Filing insights

Eight directors elected; shareholders approved non-binding executive compensation and ratified Grant Thornton as auditor for 2026.

About Cts Corp
Market cap
$1.9B
1Y TSR
+45.1%
3Y TSR
+11.4%
Board grade
C+
Sector
Technology
CEO
Kieran M O'Sullivan
Last annual meeting: May 14, 2026 · View full Cts Corp profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2026

 

 

CTS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Indiana

1-4639

35-0225010

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4925 Indiana Avenue

 

Lisle, Illinois

 

60532

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (630) 577-8800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, no par value

 

CTS

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Shareholders (the “Annual Meeting”) on May 14, 2026. At the Annual Meeting, all director nominees were elected. Proposals 2 and 3 were approved. The proposals below are described in more detail in the Company’s definitive proxy statement filed on April 2, 2026 (the “Proxy Statement”) for the Annual Meeting. The final results were as follows:

PROPOSAL 1 – Election of eight directors until the next annual meeting of shareholders:

 

DIRECTOR NOMINEE

 

NUMBER OF VOTES FOR

 

 

NUMBER OF VOTES AGAINST

 

 

NUMBER OF ABSTENTIONS

 

 

NUMBER OF BROKER NON-VOTES

 

Donna M. Costello

 

25,587,200

 

 

 

97,050

 

 

 

9,188

 

 

 

825,870

 

Amy M. Dodrill

 

 

25,634,413

 

 

 

47,914

 

 

 

11,111

 

 

 

825,870

 

William S. Johnson

 

25,186,497

 

 

 

497,885

 

 

 

9,056

 

 

 

825,870

 

Kimberly Banks MacKay

 

 

25,638,499

 

 

 

47,531

 

 

 

7,408

 

 

 

825,870

 

Kieran M. O’Sullivan

 

25,380,534

 

 

 

305,629

 

 

 

7,275

 

 

 

825,870

 

Robert A. Profusek

 

24,632,574

 

 

 

1,053,874

 

 

 

6,990

 

 

 

825,870

 

Randy L. Stone

 

25,631,137

 

 

 

53,245

 

 

 

9,056

 

 

 

825,870

 

Alfonso G. Zulueta

 

 

25,552,599

 

 

 

127,033

 

 

 

13,806

 

 

 

825,870

 

 

PROPOSAL 2 – Approval, on a non-binding advisory basis, of the compensation of our named executive officers as described in the Proxy Statement:

 

NUMBER OF VOTES FOR

 

 

NUMBER OF VOTES AGAINST

 

 

NUMBER OF ABSTENTIONS

 

 

NUMBER OF BROKER NON-VOTES

 

 

25,021,506

 

 

 

655,182

 

 

 

16,750

 

 

 

825,870

 

 

PROPOSAL 3 – Ratification of the appointment of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026:

 

NUMBER OF VOTES FOR

 

NUMBER OF VOTES AGAINST

 

NUMBER OF ABSTENTIONS

 

 

25,989,929

 

 

 

522,284

 

 

 

7,095

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

CTS Corporation

 

 

 

 

Date:

May 19, 2026

By:

/s/ Mark Pacioni

 

 

 

Mark Pacioni

Vice President, Chief Legal and Administrative Officer and Corporate Secretary

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cts Corp (CTS)

Reference

Frequently asked questions

When did Cts Corp file this 8-K?
Cts Corp (CTS) filed this Current Report (Form 8-K) with the SEC on May 19, 2026. The accession number assigned by EDGAR is 0001193125-26-230702.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Eight directors elected; shareholders approved non-binding executive compensation and ratified Grant Thornton as auditor for 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Cts Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Cts Corp has filed under CIK 26058, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer